Results 91 to 100 of about 8,451 (198)
ABSTRACT Background To systematically evaluate the local biomarkers correlated with olfactory dysfunction (OD) in chronic rhinosinusitis (CRS). Methods A systematic review was conducted in CINAHL, Cochrane Library, PubMed, and Scopus from inception to July 2025.
David Kayekjian +4 more
wiley +1 more source
Mepolizumab treatment in patients with severe eosinophilic asthma. [PDF]
BACKGROUND: Some patients with severe asthma have frequent exacerbations associated with persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled glucocorticoids with or without oral glucocorticoids.
Pavord, Ian D. +42 more
core +1 more source
ABSTRACT Introduction Artificial intelligence (AI) is a branch of technology enabling machines to emulate complex human skills; it can also entail problem‐solving using bioinspired methods. It is used for automating systematic literature reviews (SLR), that is, defining a clinical question, locating relevant literature, preliminary screening, study ...
Ana M. Barragán +5 more
wiley +1 more source
Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma [PDF]
Pranabashis Haldar Respiratory Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, UK Abstract: Mepolizumab (Nucala®) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add ...
Pranabashis Haldar +2 more
core +1 more source
Efficacy of mepolizumab and omalizumab combination therapy in uncontrolled asthma
ObjectiveResults of biological therapies are often encouraging for severe asthma who are phenotyped as Type 2 inflammation. Unfortunately, some patients do not achieve the desired responses.
Fuat Erel +17 more
core +1 more source
Phenotypic Clusters of Severe Asthma and Response to Dupilumab in Real‐World Practice
ABSTRACT Background Severe asthma is a heterogeneous disease with variable clinical and inflammatory profiles that may influence responses to biological therapies. Identifying phenotypic clusters may help optimize patient selection and treatment outcomes.
Daria S. Fomina +9 more
wiley +1 more source
To date, most studies to identify biomarkers associated with response to the anti-interleukin 5 agent, mepolizumab, and to the anti-immunoglobulin E agent, omalizumab have focused on clinically available biomarkers, such as the peripheral blood ...
Ayobami Akenroye +3 more
doaj +1 more source
Jean-Pierre Llanos,1 Hector Ortega,1 Michael Bogart,2 Elizabeth R Packnett,3 Janna Manjelievskaia,3 Christopher F Bell,2 Beth Hahn2 1Respiratory, US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2US Value Evidence and Outcomes, US Medical ...
Llanos JP +6 more
doaj
We present a patient with long‐standing severe Type 2 asthma complicated by recurrent exacerbations of an infective nature that was ultimately found to be associated with gastric band slippage causing gastric stenosis and delayed gastric emptying. Exacerbations ceased after surgical intervention and removal of the band.
Gerardo Arwi +2 more
wiley +1 more source
The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma [PDF]
Airidas Rimkunas,1 Andrius Januskevicius,1 Egle Vasyle,1 Jolita Palacionyte,2 Virginija Kalinauskaite-Zukauske,2 Skaidrius Miliauskas,2 Kestutis Malakauskas1,2 1Laboratory of Pulmonology, Department of Pulmonology, Lithuanian University of Health ...
Palacionyte J +6 more
core

